See more : Formula Systems (1985) Ltd. (FORTY) Income Statement Analysis – Financial Results
Complete financial analysis of Jaguar Health, Inc. (JAGX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Jaguar Health, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Nippon Sanso Holdings Corporation (4091.T) Income Statement Analysis – Financial Results
- Xinjiang Goldwind Science & Technology Co., Ltd. (2208.HK) Income Statement Analysis – Financial Results
- Wirecard AG (0O8X.L) Income Statement Analysis – Financial Results
- Lvji Technology Holdings Inc. (1745.HK) Income Statement Analysis – Financial Results
- Apex Development Public Company Limited (APEX.BK) Income Statement Analysis – Financial Results
Jaguar Health, Inc. (JAGX)
About Jaguar Health, Inc.
Jaguar Health, Inc., a commercial stage pharmaceuticals company, focuses on developing prescription medicines for people and animals with gastrointestinal distress, specifically chronic, and debilitating diarrhea. The company operates through two segments, Human Health and Animal Health. It markets Mytesi for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. The company also develops Crofelemer for multiple possible follow-on indications, including cancer therapy-related diarrhea; orphan-drug indications for symptomatic relief of diarrhea in infants and children with congenital diarrheal disorders and for adult and pediatric patients for short bowel syndrome with intestinal failure with; supportive care for diarrhea relief in inflammatory bowel diseases; diarrhea-predominant irritable bowel syndrome; and for idiopathic/functional diarrhea. In addition, it develops lechlemer, a second-generation anti-secretory agent for cholera; and Canalevia, an oral plant-based drug candidate to treat chemotherapy-induced diarrhea in dogs and exercise-induced diarrhea in dogs. Jaguar Health, Inc. was founded in 2013 and is headquartered in San Francisco, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 9.76M | 11.96M | 4.34M | 9.39M | 5.78M | 4.42M | 4.36M | 141.52K | 258.38K | 0.00 |
| Cost of Revenue | 2.04M | 2.02M | 2.33M | 3.28M | 3.82M | 2.77M | 880.41K | 51.97K | 123.46K | 0.00 |
| Gross Profit | 7.72M | 9.94M | 2.00M | 6.11M | 1.96M | 1.65M | 3.48M | 89.56K | 134.92K | 0.00 |
| Gross Profit Ratio | 79.13% | 83.11% | 46.18% | 65.05% | 33.93% | 37.37% | 79.81% | 63.28% | 52.22% | 0.00% |
| Research & Development | 18.60M | 17.65M | 15.08M | 6.41M | 5.82M | 5.15M | 4.27M | 7.21M | 6.48M | 4.22M |
| General & Administrative | 16.59M | 17.87M | 17.10M | 14.39M | 13.50M | 12.28M | 11.25M | 5.98M | 5.34M | 0.00 |
| Selling & Marketing | 6.46M | 8.84M | 8.89M | 6.61M | 6.94M | 9.83M | 3.08M | 485.44K | 765.09K | 0.00 |
| SG&A | 23.05M | 26.71M | 26.00M | 21.00M | 20.44M | 22.11M | 14.33M | 6.47M | 6.10M | 4.10M |
| Other Expenses | 371.00K | 950.00K | -765.00K | 190.00K | 648.80K | 315.69K | 88.55K | -11.05K | -27.28K | 0.00 |
| Operating Expenses | 42.02M | 44.35M | 41.08M | 27.41M | 26.91M | 27.26M | 18.60M | 13.68M | 12.58M | 8.32M |
| Cost & Expenses | 44.05M | 46.37M | 43.41M | 30.69M | 30.72M | 30.03M | 19.48M | 13.73M | 12.70M | 8.32M |
| Interest Income | 0.00 | 12.72M | 8.42M | 2.79M | 5.73M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 6.38M | 12.72M | 8.42M | 2.79M | 5.73M | 2.63M | 1.21M | 985.55K | 3.32M | 0.00 |
| Depreciation & Amortization | 1.16M | 2.29M | 1.83M | 2.28M | 1.93M | 1.75M | 584.34K | 47.49K | 5.16K | -51.42K |
| EBITDA | -33.13M | -33.38M | -42.35M | -28.74M | -30.87M | -27.77M | -11.13M | -13.70M | -12.97M | -8.37M |
| EBITDA Ratio | -339.42% | -260.73% | -914.88% | -257.61% | -397.20% | -454.56% | 100.27% | -9,459.45% | -4,620.54% | 0.00% |
| Operating Income | -34.29M | -34.42M | -39.07M | -21.30M | -24.95M | -30.82M | -34.25M | -13.59M | -12.45M | -8.32M |
| Operating Income Ratio | -351.31% | -287.85% | -901.36% | -227.00% | -431.98% | -697.98% | -785.27% | -9,599.84% | -4,816.67% | 0.00% |
| Total Other Income/Expenses | -7.61M | -13.98M | -11.89M | -7.16M | -9.58M | -1.32M | -902.80K | -1.15M | -3.85M | -293.91K |
| Income Before Tax | -41.90M | -48.40M | -52.60M | -33.81M | -38.53M | -32.15M | -35.15M | -14.73M | -16.29M | -8.61M |
| Income Before Tax Ratio | -429.27% | -404.78% | -1,213.38% | -360.25% | -667.15% | -727.92% | -805.97% | -10,410.87% | -6,305.24% | 0.00% |
| Income Tax Expense | 0.00 | -941.00K | 7.65M | 2.98M | 10.00K | -1.28M | -13.18M | 1.14M | 3.82M | 345.34K |
| Net Income | -41.30M | -47.45M | -60.25M | -36.79M | -38.54M | -32.15M | -21.97M | -14.73M | -16.29M | -8.61M |
| Net Income Ratio | -423.11% | -396.91% | -1,389.87% | -392.02% | -667.32% | -727.92% | -503.73% | -10,410.87% | -6,305.24% | 0.00% |
| EPS | -107.42 | -36.18 | -101.07 | -214.22 | -1.75K | -15.51K | -27.26K | -249.73K | -479.16K | -204.99K |
| EPS Diluted | -107.42 | -36.18 | -101.07 | -214.22 | -1.75K | -15.51K | -27.26K | -249.73K | -479.16K | -204.99K |
| Weighted Avg Shares Out | 384.47K | 1.31M | 596.15K | 171.75K | 22.07K | 2.07K | 806.00 | 59.00 | 34.00 | 42.00 |
| Weighted Avg Shares Out (Dil) | 384.47K | 1.31M | 596.15K | 171.75K | 22.07K | 2.07K | 806.00 | 59.00 | 34.00 | 42.00 |
Jaguar Health's stock drops after results supporting ‘paramount' trial have not been received yet
Top Line Data for Jaguar Health's Pivotal Phase 3 OnTarget Trial for Prophylaxis of Diarrhea in Adult Cancer Patients Receiving Targeted Therapy Forthcoming
Jaguar Health, Inc. (JAGX) Q3 2023 Earnings Call Transcript
Jaguar Health Reports Third Quarter 2023 Financial Results
Jaguar Health Announces New Employee Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Breast Cancer Related Results of Groundbreaking Napo Pharmaceuticals (a Jaguar Health Family Company) Supported Study on Quality of Life for Cancer Patients and Survivors Accepted for Presentation at the December 2023 San Antonio Breast Cancer Symposium
Jaguar Health Receives Additional 180-day Grace Period to Regain Compliance with Nasdaq's Bid Price Rule
Jaguar Health to Hold Investor Webcast Tuesday, November 14th at 8:30 AM Eastern Regarding Q3 2023 Financials & Corporate Updates
REMINDER: Jaguar Health to Host Virtual Educational Webinar on Rare Intestinal Failure Diseases with Leading Gastroenterologists and Nutrition Experts November 8th from 1:00 PM to 2:30 PM EST
Jaguar Health Enters Exclusive Crofelemer Revenue Sharing License and Commercialization Agreement with Quadri Pharmaceuticals Store for Rare Intestinal Failure Diseases in Middle East Markets
Source: https://incomestatements.info
Category: Stock Reports